Eli Lilly acquires CoLucid to Expand Pain Portfolio
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 2 (Table of Contents)
Published: 4 Feb-2017
DOI: 10.3833/pdr.v2017.i2.2223 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Eli Lilly has entered into an agreement to acquire all shares of CoLucid Pharmaceuticals for a purchase price of US$960 M to gain a late stage asset, lasmiditan, which is in development for the treatment of migraine...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS